Integrated therapy of kidney cancer

R. Longo, M. R. D'Andrea, R. Sarmiento, F. Salerno, G. Gasparini

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Historically, treatment options for metastatic renal cell carcinoma (RCC) have been limited because of inherent tumor resistance to chemotherapy and radiotherapy. The only approved drug for RCC in the past 30 years has been high-dose interleukin-2. Its benefit is observed in a small percentage (20%-25%) of highly selected good performance status RCC patients. The treatment of advanced RCC has recently undergone a major change with the development of potent angiogenesis inhibitors and targeted agents. In fact, advanced RCC is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF); thereafter, antiangiogenic strategies have become an attractive approach. Several multitargeted tyrosine kinase inhibitors (sorafenib and sunitinib) have already been approved for the treatment of advanced RCC; bevacizumab, a monoclonal antibody anti-VEGF, has shown promising clinical activity. Temsirolimus, a derivative of rapamycin (CCI-779), has also shown a survival advantage over interferon in advanced, poor-prognosis RCC patients. The aim of this review is to describe these agents in terms of mechanisms of action, efficacy, and toxicity profile and also to analyze future development strategies.

Original languageEnglish
JournalAnnals of Oncology
Volume18
Issue numberSUPPL. 6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Therapeutics
Angiogenesis Inhibitors
Sirolimus
Protein-Tyrosine Kinases
Interferons
Interleukin-2
Blood Vessels
Neoplasms
Radiotherapy
Monoclonal Antibodies
Drug Therapy
Survival
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Kidney cancer
  • Metastatic renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Longo, R., D'Andrea, M. R., Sarmiento, R., Salerno, F., & Gasparini, G. (2007). Integrated therapy of kidney cancer. Annals of Oncology, 18(SUPPL. 6). https://doi.org/10.1093/annonc/mdm244

Integrated therapy of kidney cancer. / Longo, R.; D'Andrea, M. R.; Sarmiento, R.; Salerno, F.; Gasparini, G.

In: Annals of Oncology, Vol. 18, No. SUPPL. 6, 06.2007.

Research output: Contribution to journalArticle

Longo, R, D'Andrea, MR, Sarmiento, R, Salerno, F & Gasparini, G 2007, 'Integrated therapy of kidney cancer', Annals of Oncology, vol. 18, no. SUPPL. 6. https://doi.org/10.1093/annonc/mdm244
Longo R, D'Andrea MR, Sarmiento R, Salerno F, Gasparini G. Integrated therapy of kidney cancer. Annals of Oncology. 2007 Jun;18(SUPPL. 6). https://doi.org/10.1093/annonc/mdm244
Longo, R. ; D'Andrea, M. R. ; Sarmiento, R. ; Salerno, F. ; Gasparini, G. / Integrated therapy of kidney cancer. In: Annals of Oncology. 2007 ; Vol. 18, No. SUPPL. 6.
@article{998083a5d87846478fd71fa421e6ad5f,
title = "Integrated therapy of kidney cancer",
abstract = "Historically, treatment options for metastatic renal cell carcinoma (RCC) have been limited because of inherent tumor resistance to chemotherapy and radiotherapy. The only approved drug for RCC in the past 30 years has been high-dose interleukin-2. Its benefit is observed in a small percentage (20{\%}-25{\%}) of highly selected good performance status RCC patients. The treatment of advanced RCC has recently undergone a major change with the development of potent angiogenesis inhibitors and targeted agents. In fact, advanced RCC is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF); thereafter, antiangiogenic strategies have become an attractive approach. Several multitargeted tyrosine kinase inhibitors (sorafenib and sunitinib) have already been approved for the treatment of advanced RCC; bevacizumab, a monoclonal antibody anti-VEGF, has shown promising clinical activity. Temsirolimus, a derivative of rapamycin (CCI-779), has also shown a survival advantage over interferon in advanced, poor-prognosis RCC patients. The aim of this review is to describe these agents in terms of mechanisms of action, efficacy, and toxicity profile and also to analyze future development strategies.",
keywords = "Chemotherapy, Kidney cancer, Metastatic renal cell carcinoma",
author = "R. Longo and D'Andrea, {M. R.} and R. Sarmiento and F. Salerno and G. Gasparini",
year = "2007",
month = "6",
doi = "10.1093/annonc/mdm244",
language = "English",
volume = "18",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Integrated therapy of kidney cancer

AU - Longo, R.

AU - D'Andrea, M. R.

AU - Sarmiento, R.

AU - Salerno, F.

AU - Gasparini, G.

PY - 2007/6

Y1 - 2007/6

N2 - Historically, treatment options for metastatic renal cell carcinoma (RCC) have been limited because of inherent tumor resistance to chemotherapy and radiotherapy. The only approved drug for RCC in the past 30 years has been high-dose interleukin-2. Its benefit is observed in a small percentage (20%-25%) of highly selected good performance status RCC patients. The treatment of advanced RCC has recently undergone a major change with the development of potent angiogenesis inhibitors and targeted agents. In fact, advanced RCC is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF); thereafter, antiangiogenic strategies have become an attractive approach. Several multitargeted tyrosine kinase inhibitors (sorafenib and sunitinib) have already been approved for the treatment of advanced RCC; bevacizumab, a monoclonal antibody anti-VEGF, has shown promising clinical activity. Temsirolimus, a derivative of rapamycin (CCI-779), has also shown a survival advantage over interferon in advanced, poor-prognosis RCC patients. The aim of this review is to describe these agents in terms of mechanisms of action, efficacy, and toxicity profile and also to analyze future development strategies.

AB - Historically, treatment options for metastatic renal cell carcinoma (RCC) have been limited because of inherent tumor resistance to chemotherapy and radiotherapy. The only approved drug for RCC in the past 30 years has been high-dose interleukin-2. Its benefit is observed in a small percentage (20%-25%) of highly selected good performance status RCC patients. The treatment of advanced RCC has recently undergone a major change with the development of potent angiogenesis inhibitors and targeted agents. In fact, advanced RCC is a highly vascular tumor associated with expression of vascular endothelial growth factor (VEGF); thereafter, antiangiogenic strategies have become an attractive approach. Several multitargeted tyrosine kinase inhibitors (sorafenib and sunitinib) have already been approved for the treatment of advanced RCC; bevacizumab, a monoclonal antibody anti-VEGF, has shown promising clinical activity. Temsirolimus, a derivative of rapamycin (CCI-779), has also shown a survival advantage over interferon in advanced, poor-prognosis RCC patients. The aim of this review is to describe these agents in terms of mechanisms of action, efficacy, and toxicity profile and also to analyze future development strategies.

KW - Chemotherapy

KW - Kidney cancer

KW - Metastatic renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=35748961731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748961731&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm244

DO - 10.1093/annonc/mdm244

M3 - Article

VL - 18

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 6

ER -